Angiogenesis and non-small cell lung cancer


Autoria(s): Cox, G.; Jones, J. L.; Walker, R. A.; Steward, W. P.; O'Byrne, Kenneth J.
Data(s)

2000

Resumo

Lung cancer is the commonest cause of cancer death in the western world. Recent evidence suggests that angiogenesis is related to poor prognosis in many solid tumours including non-small cell lung cancer. Angiogenesis is controlled by a complex interaction between growth and apoptotic factors, proteases and adhesion molecules. The angiogenic process may prove a target for novel therapies such as matrix metalloproteinase inhibitors, growth factor antisense RNA, growth factor receptor antagonists and naturally occurring antiangiogenic peptides. These agents may be used alone or in combination with traditional chemotherapy, radiotherapy and surgery. (C) 2000 Elsevier Science Ireland Ltd.

Identificador

http://eprints.qut.edu.au/64912/

Publicador

Elsevier Ireland Ltd

Relação

DOI:10.1016/S0169-5002(99)00096-3

Cox, G., Jones, J. L., Walker, R. A., Steward, W. P., & O'Byrne, Kenneth J. (2000) Angiogenesis and non-small cell lung cancer. Lung Cancer, 27(2), pp. 81-100.

Direitos

Copyright 2000 Elsevier Ireland

Fonte

School of Biomedical Sciences; Faculty of Health; Institute of Health and Biomedical Innovation

Palavras-Chave #Angiogenesis #Apoptosis #Growth factors #Matrix metalloproteinases #Non- small cell lung cancer #angiogenesis inhibitor #angiostatin #basic fibroblast growth factor #cyclophosphamide #endostatin #fumagillol chloroacetylcarbamate #growth factor receptor antagonist #metalloproteinase inhibitor #platelet derived endothelial cell growth factor #protein bcl 2 #protein p53 #unclassified drug #vasculotropin receptor #article #drug mechanism #growth regulation #human #human cell #lung non small cell cancer #pathophysiology #priority journal #prognosis #Angiogenesis Inhibitors #Carcinoma #Non-Small-Cell Lung #Growth Substances #Humans #Lung Neoplasms #Neovascularization #Pathologic
Tipo

Journal Article